WEKO3
アイテム
{"_buckets": {"deposit": "b3291f4c-f5e1-421b-a485-2ce0cf7fbecc"}, "_deposit": {"id": "25141", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "25141"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:00025141", "sets": ["501"]}, "author_link": ["75038", "75039", "75040", "75041", "75042"], "item_10_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2017-12", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "12", "bibliographicPageEnd": "e85", "bibliographicPageStart": "e75", "bibliographicVolumeNumber": "17", "bibliographic_titles": [{"bibliographic_title": "Clinical Lymphoma Myeloma and Leukemia", "bibliographic_titleLang": "en"}]}]}, "item_10_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "The existence of synchronous multiple primary malignant tumors was not a significant risk factor for patients with newly diagnosed hematological malignancies. It is important to provide adequate treatment to both hematological malignancies and solid tumors appropriately. Background: Hematological malignancies are occasionally observed with synchronous multiple primary malignant tumors (sMPMTs) at diagnosis. We aimed to clarify the impact of sMPMTs on newly diagnosed hematological malignancies and determine the optimal treatment strategies. Patients and Methods: We analyzed the outcomes of 649 patients with hematological malignancies, including 19 patients with sMPMTs (2.9%), and compared the outcomes between patients with and without sMPMTs. Results: The overall survival (OS) and disease-free survival (DFS) rates for patients with sMPMTs were 77% and 70%, respectively, at 2 years; these rates were not statistically different from those for patients without sMPMTs (P = .17 and P = .64, respectively). Multivariate analysis showed that the presence of sMPMTs was not a significant prognostic factor for OS, DFS, or relapse (hazard ratio [HR] 1.48, 95% confidence interval [CI] 0.65-3.38, P = .35; HR 0.97, 95% CI 0.46-2.10, P = .97; and HR 0.79, 95% CI 0.29-2.14, P= .65). In patients with sMPMTs, the order of treatment was not a significant prognostic factor. However, discontinuation of treatment was a marginally favorable factor and might reflect a selection bias. Conclusion: The presence of sMPMTs was not a significant risk factor for patients with newly diagnosed hematological malignancies. It is important to provide adequate treatment for both hematological malignancies and solid tumors at the physician’s discretion.", "subitem_description_language": "en", "subitem_description_type": "Abstract"}]}, "item_10_identifier_60": {"attribute_name": "URI", "attribute_value_mlt": [{"subitem_identifier_type": "DOI", "subitem_identifier_uri": "http://doi.org/10.1016/j.clml.2017.09.006"}, {"subitem_identifier_type": "HDL", "subitem_identifier_uri": "http://hdl.handle.net/2237/27362"}]}, "item_10_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Elsevier", "subitem_publisher_language": "en"}]}, "item_10_relation_11": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.1016/j.clml.2017.09.006", "subitem_relation_type_select": "DOI"}}]}, "item_10_rights_12": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/", "subitem_rights_language": "en"}]}, "item_10_select_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "author"}]}, "item_10_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "2152-2650", "subitem_source_identifier_type": "PISSN"}]}, "item_1615787544753": {"attribute_name": "出版タイプ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "open access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_abf2"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Nishiwaki, Satoshi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "75038", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Okuno, Shingo", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "75039", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Suzuki, Kotaro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "75040", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kurahashi, Shingo", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "75041", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sugiura, Isamu", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "75042", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2018-12-01"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "CLML_2017_435_Original_accepted_V1.pdf", "filesize": [{"value": "359.0 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_note", "mimetype": "application/pdf", "size": 359000.0, "url": {"label": "CLML_2017_435_Original_accepted_V1.pdf ファイル公開日: 2018/12/01", "objectType": "fulltext", "url": "https://nagoya.repo.nii.ac.jp/record/25141/files/CLML_2017_435_Original_accepted_V1.pdf"}, "version_id": "0937d703-a1e4-46df-9616-41f02c90e7c6"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Hematological malignancies", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Order of treatment", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Solid tumors", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Synchronous multiple primary malignant tumors", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Treatment discontinuation", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Impact of Synchronous Multiple Primary Malignant Tumors on Newly Diagnosed Hematological Malignancies", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Impact of Synchronous Multiple Primary Malignant Tumors on Newly Diagnosed Hematological Malignancies", "subitem_title_language": "en"}]}, "item_type_id": "10", "owner": "1", "path": ["501"], "permalink_uri": "http://hdl.handle.net/2237/27362", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2018-02-06"}, "publish_date": "2018-02-06", "publish_status": "0", "recid": "25141", "relation": {}, "relation_version_is_last": true, "title": ["Impact of Synchronous Multiple Primary Malignant Tumors on Newly Diagnosed Hematological Malignancies"], "weko_shared_id": -1}
Impact of Synchronous Multiple Primary Malignant Tumors on Newly Diagnosed Hematological Malignancies
http://hdl.handle.net/2237/27362
http://hdl.handle.net/2237/27362c8805072-ea51-467b-9578-eab670243421
名前 / ファイル | ライセンス | アクション |
---|---|---|
![]() |
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2018-02-06 | |||||
タイトル | ||||||
タイトル | Impact of Synchronous Multiple Primary Malignant Tumors on Newly Diagnosed Hematological Malignancies | |||||
言語 | en | |||||
著者 |
Nishiwaki, Satoshi
× Nishiwaki, Satoshi× Okuno, Shingo× Suzuki, Kotaro× Kurahashi, Shingo× Sugiura, Isamu |
|||||
アクセス権 | ||||||
アクセス権 | open access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||
権利 | ||||||
言語 | en | |||||
権利情報 | © 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Hematological malignancies | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Order of treatment | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Solid tumors | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Synchronous multiple primary malignant tumors | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Treatment discontinuation | |||||
抄録 | ||||||
内容記述 | The existence of synchronous multiple primary malignant tumors was not a significant risk factor for patients with newly diagnosed hematological malignancies. It is important to provide adequate treatment to both hematological malignancies and solid tumors appropriately. Background: Hematological malignancies are occasionally observed with synchronous multiple primary malignant tumors (sMPMTs) at diagnosis. We aimed to clarify the impact of sMPMTs on newly diagnosed hematological malignancies and determine the optimal treatment strategies. Patients and Methods: We analyzed the outcomes of 649 patients with hematological malignancies, including 19 patients with sMPMTs (2.9%), and compared the outcomes between patients with and without sMPMTs. Results: The overall survival (OS) and disease-free survival (DFS) rates for patients with sMPMTs were 77% and 70%, respectively, at 2 years; these rates were not statistically different from those for patients without sMPMTs (P = .17 and P = .64, respectively). Multivariate analysis showed that the presence of sMPMTs was not a significant prognostic factor for OS, DFS, or relapse (hazard ratio [HR] 1.48, 95% confidence interval [CI] 0.65-3.38, P = .35; HR 0.97, 95% CI 0.46-2.10, P = .97; and HR 0.79, 95% CI 0.29-2.14, P= .65). In patients with sMPMTs, the order of treatment was not a significant prognostic factor. However, discontinuation of treatment was a marginally favorable factor and might reflect a selection bias. Conclusion: The presence of sMPMTs was not a significant risk factor for patients with newly diagnosed hematological malignancies. It is important to provide adequate treatment for both hematological malignancies and solid tumors at the physician’s discretion. | |||||
言語 | en | |||||
内容記述タイプ | Abstract | |||||
出版者 | ||||||
言語 | en | |||||
出版者 | Elsevier | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプresource | http://purl.org/coar/resource_type/c_6501 | |||||
タイプ | journal article | |||||
出版タイプ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
DOI | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | DOI | |||||
関連識別子 | https://doi.org/10.1016/j.clml.2017.09.006 | |||||
ISSN | ||||||
収録物識別子タイプ | PISSN | |||||
収録物識別子 | 2152-2650 | |||||
書誌情報 |
en : Clinical Lymphoma Myeloma and Leukemia 巻 17, 号 12, p. e75-e85, 発行日 2017-12 |
|||||
著者版フラグ | ||||||
値 | author | |||||
URI | ||||||
識別子 | http://doi.org/10.1016/j.clml.2017.09.006 | |||||
識別子タイプ | DOI | |||||
URI | ||||||
識別子 | http://hdl.handle.net/2237/27362 | |||||
識別子タイプ | HDL |